TYRA
Tyra Biosciences, Inc.
Key Financials
Operating Income
$-132762000
↓ 27.4%
Net Income
$-119947000
↓ 38.7%
Total Liabilities
$23.4M
↑ 14.8%
EPS (Diluted)
$-2.01
↓ 33.1%
Cash & Equivalents
$77.4M
↓ 15.9%
Shareholders' Equity
$259.2M
↓ 24.5%
Total Assets
$282.6M
↓ 22.3%
Operating Cash Flow
$-95142000.00
↓ 36.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 9/21/2026 | View on SEC |
| 4 | 9/17/2026 | View on SEC |
| 4 | 9/17/2026 | View on SEC |
| 4 | 9/17/2026 | View on SEC |
| SCHEDULE 13D/A | 9/17/2026 | View on SEC |
| 4 | 9/17/2026 | View on SEC |
| SCHEDULE 13G | 9/17/2026 | View on SEC |
| 8-K | 9/15/2026 | View on SEC |
| 424B5 | 9/15/2026 | View on SEC |
| FWP | 9/14/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TYRA |
| Company Name | Tyra Biosciences, Inc. |
| CIK | 1863127 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (619) 728-4760 |